< Back to Management Team

Gregory C. Critchfield, MD, MS

Chairman, President, and CEO

“The work that Sera Prognostics is doing is groundbreaking and game-changing. It was so important to me to be a part of this effort that I left retirement to help Sera develop technologies to improve outcomes for mothers and their babies.”

Dr. Critchfield joined the Sera Prognostics Board of Directors in August 2010, became Chairman in April 2011, and was appointed as Sera’s CEO in November 2011. Before joining Sera, Dr. Critchfield was president of Myriad Genetics Laboratories from 1998-2010. Under his leadership, Myriad launched seven novel molecular diagnostic products across a variety of technology platforms and increased annual revenues from $2.2 million to $326.5 million. Prior to Myriad, he served as senior vice president/chief medical and science officer at Corning Clinical Laboratories/Quest Diagnostics. Dr. Critchfield currently serves on the boards of Integrated Diagnostics, Nodality, and Metamark Genetics. He holds a B.S. in Microbiology from BYU, an M.D. from the University of Utah College of Medicine, and an M.S. in Biophysical Sciences from the University of Minnesota.